CN Patent

CN104203953A — (s)-4-氨基-n-(1-(4-氯苯基)-3-羟丙基)-1-(7h-吡咯并[2,3-d]嘧啶-4-基)哌啶-4-甲酰胺的晶型

Assigned to AstraZeneca AB · Expires 2014-12-10 · 11y expired

What this patent protects

本发明公开了(S)-4-氨基-N-(1-(4-氯苯基)-3-羟丙基)-1-(7H-吡咯并[2,3-d]嘧啶-4-基)哌啶-4-甲酰胺的某些新固态形式、用于制备这种固态形式的方法、包含这种固体形式的药物组合物、和这种形式在治疗中的用途。

USPTO Abstract

本发明公开了(S)-4-氨基-N-(1-(4-氯苯基)-3-羟丙基)-1-(7H-吡咯并[2,3-d]嘧啶-4-基)哌啶-4-甲酰胺的某些新固态形式、用于制备这种固态形式的方法、包含这种固体形式的药物组合物、和这种形式在治疗中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN104203953A
Jurisdiction: CN
Classification: —
Expires: 2014-12-10
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.